PHVS Pharvaris N.V.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel, potent small-molecule bradykinin B2 receptor antagonist. PHA121 is the only oral B2-receptor antagonist in clinical development, currently under Phase 1 clinical study. Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

$7.67
As of 09/30/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  The Netherlands
Country of incorporation:  
IPO date:  02/04/2021
Outstanding shares:  33,151,881
Average volume:  5,620
Market cap:   $254,274,927
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.33
PS ratio:   0.00
Return on equity:   -27.62%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy